Hyderabad: Dr. Reddy's Laboratories Limited has announced that the United States Food and Drug Administration (USFDA) has classified the outcome of its Good Manufacturing Practices (GMP) inspection at the company's formulations manufacturing facility in Bachupally, Hyderabad, as Voluntary Action Indicated (VAI).

The company further confirmed that the inspection has been officially closed.

In a regulatory update, Dr. Reddy’s Laboratories stated that the inspection was conducted at its Formulations Manufacturing Facility (FTO-3), located in Bachupally, Hyderabad. The company had initially informed the stock exchanges about the GMP inspection through an earlier communication dated August 14, 2026.

Following the inspection, the USFDA classified the outcome as Voluntary Action Indicated (VAI). The regulatory authority also concluded the inspection process, officially closing it under 21 CFR 20.64(d)(3). The company confirmed the development through its regulatory communication to the stock exchanges.

The VAI classification indicates that the inspection outcome has been placed in the Voluntary Action Indicated category. The company did not disclose further details regarding specific inspectional observations or corrective measures in its latest regulatory communication.

Dr. Reddy’s Laboratories is a Hyderabad-headquartered multinational pharmaceutical company with operations across several international markets. Established in 1984, the company has developed a strong presence in the global pharmaceutical industry through its portfolio of generic medicines, active pharmaceutical ingredients (APIs), branded generics, biosimilars and differentiated formulations.

The company operates across multiple therapeutic segments, including gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its business activities encompass the development, manufacturing and marketing of pharmaceutical products for domestic and international markets.

Dr. Reddy’s has a significant presence in regulated markets, including the United States, where pharmaceutical manufacturing facilities and product quality systems are subject to regulatory oversight. Compliance with current Good Manufacturing Practices (cGMP), quality assurance procedures and regulatory requirements remains an important aspect of its manufacturing and global supply operations.

The Bachupally facility forms part of the company’s pharmaceutical manufacturing infrastructure in Hyderabad. Manufacturing facilities supplying regulated international markets are required to maintain quality systems covering manufacturing processes, documentation, equipment, testing and product quality to ensure compliance with applicable regulatory standards.

Also Read: Dr Reddy's, Takeda Ink Deal to Launch Dengue Vaccine QDENGA in India's Private Market in 2027

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .